Possibilities and challenges for developing a successful vaccine for leishmaniasis by Saumya Srivastava et al.
REVIEW Open Access
Possibilities and challenges for developing
a successful vaccine for leishmaniasis
Saumya Srivastava, Prem Shankar, Jyotsna Mishra and Sarman Singh*
Abstract
Leishmaniasis is a vector-borne disease caused by different species of protozoan parasites of the genus Leishmania.
It is a major health problem yet neglected tropical diseases, with approximately 350 million people worldwide at
risk and more than 1.5 million infections occurring each year. Leishmaniasis has different clinical manifestations,
including visceral (VL or kala-azar), cutaneous (CL), mucocutaneous (MCL), diffuse cutaneous (DCL) and post
kala-azar dermal leishmaniasis (PKDL). Currently, the only mean to treat and control leishmaniasis is by rational
medications and vector control. However, the number of available drugs is limited and even these are either
exorbitantly priced, have toxic side effects or prove ineffective due to the emergence of resistant strains. On the
other hand, the vector control methods are not so efficient. Therefore, there is an urgent need for developing a
safe, effective, and affordable vaccine for the prevention of leishmaniasis. Although in recent years a large body of
researchers has concentrated their efforts on this issue, yet only three vaccine candidates have gone for clinical trial,
until date. These are: (i) killed vaccine in Brazil for human immunotherapy; (ii) live attenuated vaccine for humans in
Uzbekistan; and (iii) second-generation vaccine for dog prophylaxis in Brazil. Nevertheless, there are at least half a
dozen vaccine candidates in the pipeline. One can expect that, in the near future, the understanding of the whole
genome of Leishmania spp. will expand the vaccine discovery and strategies that may provide novel vaccines. The
present review focuses on the development and the status of various vaccines and potential vaccine candidates
against leishmaniasis.
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Background
Leishmaniasis is a vector-borne disease caused by
protozoan parasites belonging to the genus Leishmania.
Leishmaniasis remained one of the world’s most neglected
diseases until few years ago. It is prevalent in at least 88
countries across the tropical and subtropical regions of
Africa, Asia, the Mediterranean, Southern Europe and
South and Central Americas. Most of these (72 of 88) are
developing countries. Approximately 12 million people
are infected with a species of Leishmania at any given
time point [1].
The causative agent, the Leishmania parasite, is trans-
mitted through the bites of a tiny (2–3 mm long) female
insect vectors, the phlebotomine sand flies. There are
about 500 known Phlebotomine spp. but only 30 of these
are incriminated in the transmission of leishmaniasis [2].
The female sand fly needs a blood meal for ovulation
and egg development. While sucking the blood from an
infected person or animal, the sand fly becomes infected
with Leishmania spp. Over a period of 4 to 25 days, the
parasites transform from the amastigote to promastigote
stage and multiply in the gut of an infected sand fly vec-
tor. When the infected sand fly feeds on another person
or animal, the promastigotes (an actively motile form of
parasite) are inoculated in the new host and thus trans-
mission cycle completes [2].
The clinical manifestations of leishmaniasis in humans
depend on complex interactions between the virulence
characteristics of the infecting Leishmania spp. and the
immune responses of its host. The disease can manifest
in a number of forms ranging from simple cutaneous
ulcers to involvement of the liver and other visceral
organs causing highly fatal visceral disease or kala-azar
(KA). Accordingly, there are at least, three major clinical
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forms of the disease, the visceral leishmaniasis (VL), cuta-
neous leishmaniasis (CL) and mucocutaneous leishmania-
sis (MCL). There are other forms also which include
diffuse cutaneous leishmaniasis (DCL) and post kala-azar
dermal leishmaniasis (PKDL) and these are often linked to
host immune status as reviewed elsewhere [3]. For treat-
ment of leishmaniasis the most commonly used drugs have
been pentavalent antimonials, oral miltefosine, amphoteri-
cin B, liposomal amphotericin B and paromomycin. Major
problems associated with these drugs are high cost, tox-
icity, duration of treatment, route of administration and
the development of drug-resistant parasites [4].
However, taking clues from the fact that individuals
once infected with Leishmania spp. after recovery be-
come resistant to re-infections, efforts have been made
to develop prophylactic vaccines [3, 5]. Although there
is no licensed vaccine, as yet, against any form of leish-
maniasis, a vaccine in principle should be possible. This
assumption is based on the abundance of genetic and
biological information available about the parasite [6].
Leishmaniasis is unique among parasitic diseases be-
cause a single vaccine could successfully prevent that
disease and has the potential to protect against the infec-
tion caused by more than one species [6]. The studies of
anti-leishmanial vaccine candidates have increased in re-
cent years mainly after clarity of cell-mediated immune
mechanisms for controlling the infection. However,
current knowledge is mostly based on experimental ani-
mal models and cannot be extrapolated to humans or
dogs [7]. The immune reactions against leishmaniasis
are highly complex and while these may accelerate cure,
some responses aggravate the disease. Both these responses
depend on the particular stage of the disease, species of the
infectious agent and host immune status [8]. Therefore, it
becomes imperative to understand these pathophysio-
logical and immunological complexities before trying to
develop vaccines.
Immunological paradigm in the host and the
parasite
One of the most important aspects of Leishmania
spp. infection is the ability of these parasites to evade
and sabotage host immune responses. These characteris-
tics also allow the parasite to persist and establish
chronic infection. The protective immune response to
Leishmania infection is predominantly cell-mediated
immunity. The Th1 type immune response correlates
with resistance, whereas Th2 response is associated
with susceptibility to infection [9]. However, several fac-
tors influence resistance or susceptibility to leishmaniasis
including genetic variation of the host, genetic variation of
the parasites between species and strains, and chance fac-
tors such as the location, inoculum size and number of in-
fective bites received by the host [10].
However, two major antigen presenting cells (APCs)
which could be macrophages and/or dendritic cells
(DCs) play critical roles in mediating the resistance and
susceptibility during Leishmania infection. The macro-
phages and DCs play critical roles in the initiation, devel-
opment, and maintenance of a protective immunity against
Leishmania infection. However, the intracellular amasti-
gotes, once internalized, can modulate cell-signalling path-
ways in macrophages by a variety of mechanisms resulting
in the inhibition of cytokine responses and this can subvert
the protective potential of these cells. These mechanisms
include activation of inhibition of p38 mitogen-activated
protein kinases [11], local activation of latent TGFb32 and
NF-kB transactivation [12] and suppression of cytokine
signalling (SOCS)-3 [13]. The production of IL-12 by
DCs initiates Th1 response and protective immunity by
promoting early NK cell activities, including IFN- γ
production and cytotoxicity [14]. However, the exact
mechanisms driving differentiation of naïve CD4+T cells
into Th1 or Th2 phenotypes are still not very clear. One
of the major mechanisms used by Leishmania parasite, to
overcome the host immune response, is to inhibit the pro-
duction of Th1-polarizing cytokine, IL-12, as well as pre-
venting DCs from successfully presenting parasite
antigens to T cells [15]. It has been shown that the turn-
over and activity of other immune cells, such as granulo-
cytes, including neutrophil and eosinophil, are increased
during the human VL [16].
Current understanding of Th1/Th2 paradigm
Although our conventional understanding about Th1 vs
Th2 response in leishmaniasis is still valid, the Th2
polarization has never been able to explain the severity
of human leishmanial diseases. Recently, a number of
other T cell subsets, including regulatory T (Treg) and
Th17 cells, have been found to play important role in
the susceptibility and resistance of both experimental
and human leishmanial diseases. The Th17 and Treg
cells are widely accepted subsets with important func-
tions in the induction and control of the inflammatory
response [17]. The Th17 cells in skin and mucosa play
a vital role in the protection from several extracellular
pathogens but also incriminated in the mediation of se-
vere immune pathologies. It may be because these cells
are involved in the recruitment, migration and activation
of neutrophils [18]. IL-22 is also produced by Th17 cells,
and to a lesser extent by natural killer and Th1 cells
[18], which are particularly involved in immunity in epi-
thelial and mucosal levels [19]. IL-17 and IL-22 are in-
flammatory cytokines that play a protective role against
intracellular parasites such as Leishmania [20]. However,
the role of IL-17 and IL-22 during leishmanial infection
remains poorly defined [21]. Nevertheless, studies sug-
gested that Th17-based cytokines may be associated with
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protection against leishmaniasis. Recently, Ghosh et al.
demonstrated that administration of recombinant IL-17
and IL-23 caused a significant suppression of organ
parasite burden in mice with a marked generation of
IFN-γ and nitric oxide [22]. Along with signature Th1
cytokines, IL-17 and IL-22 were also found to have
complementary roles in protection against visceral
leishmaniasis and it was postulated that defects in the
Th17 induction could increase the risk of visceral
leishmaniasis [23]. Another cytokine IL27 is related to
IL12 and is produced by antigen presenting cells, mainly
macrophages and DCs. It is thought to be important in
the regulation of Th17 cells [24] and induction of naïve
human CD4 cells to IL10 production [25]. In mice model,
IL27 is reported to be an important cytokine in the devel-
opment of early Th1 response, and mediating suppression
of early IL4 burst [26].
The Treg cells are an important constituent of the
immune system that suppresses or regulates immune re-
sponses of other cells. These cells can be found in many
forms with the most well understood being those that
express CD4, CD25, and Foxp3 (CD4+CD25+ regulatory
T cells) ligands. The presence of these cells may, how-
ever, precondition the skin for survival of Leishmania
parasites and favour long-term parasite survival [27]. In
humans, CD4+CD25+Treg cells are found in cutaneous
lesions [28] and elevated intra lesional FoxP3 and IL-10
cells have been linked to disease progression in both
murine and human Leishmania infection [29]. However,
Th17 cytokines and the transcription factor FoxP3 have
been scarcely studied in canine leishmaniasis [30–32].
The preliminary data point to antigeninduced IL10
producing Foxp3 T cells being responsible for delayed
healing of cutaneous leishmaniasis [33, 34].
Role of toll-like receptors and nucleotide-binding
oligomerization domain
The activation of macrophage is first mediated by Toll-like
receptors (TLRs), which play an important role in the con-
trol of infection [35]. It plays an essential role in linking the
innate and adaptive immunity and enhances phagocytosis
and killing process of the parasites. Therefore, it is involved
in the first-line defence against Leishmania parasites by
triggering NF-κB activation and downstream production of
pro-inflammatory cytokines. Experimental models of vis-
ceral leishmaniasis support a protective role for TLR2, 4
and 9 in host immune responses to Leishmania infection
[36]. TLR2 has been associated with a protective role in
a number of murine models of leishmaniasis. In a L. major
murine model, the absence of TLR2 led to an increased
number of cutaneous lesions [37] and TLR2 and 3 were in-
volved in the phagocytosis of L. donovani parasites [38].
TLRs bind to myeloid differentiation factor 88 (MyD88), a
protein that interacts with several other molecules in a
signalling cascade that leads to cytokines production [39].
It was also shown that TLR4 contributes to both innate
and acquired immune responses during L. major infection
[40]. The absence of TLR4 in a knockout murine L. major
model resulted in increased cutaneous lesions [41] and
treatment with TLR4 and TLR9 agonists lessened disease
progression [42]. Tolouei and colleagues recently reported
that the mean relative gene expression and membrane ex-
pression of TLR2 and TLR4 in the macrophages of patients
with the healing form of cutaneous lesions were signifi-
cantly higher than patients with the non-healing form of
lesions. These findings advocate that there is a diverse role
of both these TLRs in the outcome of CL lesions after L.
major infection [43]. However, in human VL, Kumar et al.
reported significantly higher levels of mRNA encoding
both TLR2 and TLR4 in pre-treatment splenic aspirate
samples, but no change in TLR9 was observed between
these groups during L. donovani infection [44]. The down-
regulation of TLR3 in the lymph node has also been associ-
ated with the establishment of leishmaniasis. TLR3 is
needed for nitric oxide production and phagocytosis of the
parasite [38], therefore a downregulation of this TLR would
favour disease progression. It has also suggested that TLR2
and TLR3 play an important role in recognition of L. dono-
vani promastigote by IFNγ-primed macrophages by using
RNA interference [38]. There are limited data available on
the expression of these TLRs in human VL, particularly at
sites of infection, such as the spleen. Recently, ex-vivo ex-
pression of TLR2, 4 and 9 is also reported in the spleen
and PBMC’s of VL patients. The findings may help to
identify suitable TLR targets for TLR-based immune-
therapy or TLR agonist-based Leishmania vaccines in the
future [44].
Nucleotide-Binding Oligomerization Domain (NOD)
receptors
NOD-like receptors (NLRs) are a subset of pattern rec-
ognition receptors (PRRs) found in the cytosol that are
essential for detecting invading pathogens and initiating
the innate immune response. NLRs cooperate with TLRs
and regulate inflammatory and apoptotic response and
play key roles in the regulation of innate immune re-
sponse [45]. Other NLRs, including NLRP1, NLRP3,
and NLRC4, oligomerize to form multiprotein inflamma-
some complexes. Inflammasomes are central for cleavage
and activation of pyrogenic cytokines, IL-1β and IL-18.
NLRs and inflammasomes are linked to several auto-
immune and inflammatory diseases as well as infections
[46]. However, our knowledge of the roles of NLR in
immunity against Leishmania infections is almost non-
existent with the exception of the few studies on NLRP3.
Despite all these advancements, our understanding on
TLRs and cytoplasmic PRRs that recognize and respond
to Leishmania is rather limited.
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Immune responses conferred by spleen, liver and skin
In visceral leishmaniasis, the clinical disease proceeds
with fever, anaemia, emaciation and enlargement of the
liver and spleen [47]. The spleen is infected in all cases
of the disease and plays a central role in VL. The spleen
becomes an evident site of interaction between the im-
mune system and the Leishmania parasite, because all of
the obligatory cellular and humoral participants in the
immune response against the parasite are present in it in
large quantities. In contrast to other organs like the liver,
the spleen maintains the infection during the entire
course of disease [48]. Splenic neutrophils also play an
important role in early control of parasite growth, but
not in the liver. Neutrophil depletion at the beginning of
L. donovani infection leads to increase in parasite bur-
den. In clinical practice splenectomised patients develop
more severe and often fatal disease. In fact, IL-10 and
other cytokines produced by granuloma cells may pro-
vide conditions for the survival of Leishmania [49, 50].
The increase in the plasma cell population in lymphoid
organs is a common finding in leishmaniasis, and it
may be present at relatively early stages of the dis-
ease. However, in VL, several factors like the well-
characterized polyclonal B-cell activation [51, 52] and
production of cytokines (e.g. IFN-γ, IL-10 & IL-6)
[53, 54] and chemokines (e.g. CXCL12) may contrib-
ute to plasma cell differentiation and retention in the
red pulp of the spleen [55].
The resolution of disease in the liver is associated with
the development of granuloma which is one of the key
features of hepatic resistance [56]. These granulomas in
the liver are attributed to the development of a Th1-
dominated granulomatous response, characterized by
the high IFNγ production by CD4+ T cells, initiated by
IL-12 secreted from the DCs. IL-12 has also been shown
to facilitate activation of iNKT cells in conjunction with
TLR9 signalling [57] and TLR9 dependent IL-12 produc-
tion by DC [58]. However, as SIRP a–CD47 signalling
inhibits DC maturation and IL-12 production [59]. The
spleen is also reported to be the source of Leishmania-
specific T lymphocytes that migrate to the liver, where
parasite replication is highly active. In the liver, these
pre-activated cells become effector T lymphocytes. In re-
cent years, there has been plenty of evidence defining
immune responses of specific organs/tissues during
Leishmania infection. However, much of this informa-
tion is derived from murine models [60] and the findings
of murine studies may not necessarily be translated into
human systems [61]. Hence, there is a dearth of know-
ledge regarding the complex mechanism that the para-
site utilizes to evade the immune system in these organs.
Healthy skin contains a high number of patrolling and
resident immune cells that potentially could drive a tis-
sue resident immune response without the involvement
of lymphoid tissues. This localized lesion provides a
model for studying complex interactions of parasite spe-
cies, host immune potential and genetic factors on
which the outcome of infection depends. From an im-
munological point of view, the skin contains a network
of immune cells designed to sense infection and control
inflammation. The predominant immune cells in the hu-
man epidermis are Langerhans cells (LC), a highly spe-
cialized type of dendritic cells (DC) only present in the
skin and skin-draining lymph nodes [62]. VL and DCL
are associated with impaired T cell response against
parasite antigens. In contrast, patients with CL and
MCL have a strong type 1 immune response to a soluble
Leishmania antigen (SLA). Besides, the T cell response
of PBMCs from individuals with MCL is not appropri-
ately modulated by IL-10 and TGF-β [63]. Cutaneous
leishmaniasis usually leads to self-healing disease with
life-long immunity against re-infection. Resolution is
characterized by the induction of specific IFN-γ releas-
ing CD4+ T cells [64]. Failure to cure is associated with
elevated levels of IL-4 with low IFN-γ responses from
Leishmania-specific CD4+ T cells [65]. IL-10 is one of
the cytokines that downregulate inflammatory response,
the reduced expression of its receptor would impair IL-
10 ability to downregulate immune responses in MCL
lesions, explaining the intense inflammatory infiltrates
and tissue damage observed in this disease form. High
levels of TNF-α are also detected in the sera from MCL
patients during active disease, and the levels decrease
after therapy [66]. Increased expression of IL-10 in L.
major lesions was found to be associated with progres-
sive disease [67]. The immune mechanism of post-kala-
azar dermal leishmaniasis is different and obscure as
immunobiology of the Sudanese and South Asian PKDL
is not similar and is not well understood [68, 69]. The
PKDL patients have distinct patterns of immunity in the
skin and blood circulation. In the skin, immunity is reg-
ulated by IL-10 and FoxP3 [69, 70], because despite the
enhanced levels of IFN-γ and TNF-α, their respective re-
ceptors are downregulated [71]. Additionally, in the skin,
there is an increased presence of Th17 cells and IL-17
[70, 71]. By contrast, peripheral immunity is controlled
mostly by CD8+ T cells that are the major sources of IL-
10 and are anergic in nature [68]. However, the de-
creased frequency and secretion of CD26R promotes
disease progression in Indian PKDL [72]. Although
cellular infiltration is common in South Asian and
Sudanese PKDL, the occurrence of granulomas is absent
in the former, suggesting that granuloma formation in
the latter accounted for its self-resolving nature [73].
Recently Mukherjee et al. studied and delineated the
lesional immunopathology in terms of granuloma for-
mation, Langerhans cells, tissue macrophages along
with mRNA expression of IL-12, p40 and IL-10 [72].
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Immunological studies conducted so far indicate that
PKDL is not a localized disease, but involves complex
systemic immunity and parasitic factors [68]. However,
more studies would be needed to understand the role
of immune cells, the mechanisms that regulate their
antigen presentation and pathogen factors that influence
antigen presentation and subsequent activation of the
immune system.
Quest for vaccine against leishmaniasis
Although the geographical distribution of leishmaniasis
is restricted to particular regions of the world, the public
health concern caused by the infectious parasite is note-
worthy. The disease is endemic in 88 countries, and as
such, there is a considerable number of migratory popu-
lation with around 350 million individuals being at
risk, the impact is global. As such, current measures
to address this concern include advanced surveillance,
development of technologies for rapid assessment,
production of drugs for improved treatment, vector con-
trol and identification of animal reservoir [73]. In addition
to these important public health interventions, there has
also been an international endeavour to develop a multi-
species Leishmania vaccine [74]. At present there are no
vaccines approved for general use; however, research and
development is still underway. To date, there have been
numerous attempts to develop a successful vaccine against
leishmaniasis and there are several types of vaccine candi-
dates but mostly prophylactic (Fig. 1). In general, the vac-
cines for the prophylaxis of leishmaniasis, which are in
developmental stage, can be divided into three categories:
(i) live attenuated Leishmania vaccines, including new
genetically modified strains; (ii) killed parasite vaccines
consisting of whole killed Leishmania or fractions of the
parasite; and (iii) defined vaccines, i.e. recombinant pro-
teins, DNA vaccines and combinations thereof (Table 1).
Live attenuated vaccine
Live attenuated or first generation vaccine includes the
inoculation of attenuated parasites. The development of
a new vaccine must meet several strict criteria where
safety, reproducibility and efficacy are of utmost import-
ance [3, 5, 75, 76]. It is an appealing approach as attenu-
ated parasites closely mimic natural infection that may
lead to similar immune responses, without the danger
associated with infection with live virulent parasites.
Several procedures have been used to develop live atten-
uated Leishmania parasites, including long-term in vitro
cultures, selection for temperature sensitivity, chemical
mutagenesis and irradiation [75, 76]. This approach
known as leishmanization, used only in one country,
Uzbekistan, a mixture of live and dead L. major is
licensed as a vaccine for high-risk populations [75]. The
parasite is isolated from an active lesion to produce the
vaccine each year to overcome the problem of loss of
virulence. Although such live attenuated vaccines have
shown substantial protection against challenge in animal
models, undefined random genetic mutations and con-
cerns arising from potential reversion to virulence makes
such vaccines unsuitable for human vaccination. Indeed,
Fig. 1 Vaccines against leishmaniasis
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the persistence of asymptomatic infection, especially in
immune-compromised individuals, raises the risk of re-
version to clinical disease. Moreover, attenuations due to
undefined genome alterations can reduce effective pro-
tective immunity, either they fail to persist long enough
to elicit an immune response or lack critical epitopes to
evoke the protective response [76]. However, such mu-
tants cannot be used as vaccine candidates, because they
still carry wild-type alleles and could cause disease, espe-
cially in immunosuppressed individuals.
Another approach is the attenuation of the Leishmania
parasites by addition of suicide cassettes that lead to the
death of the parasite in response to external stimuli, an
example of which is the introduction of drug-sensitive
genes such as cytosine de-aminase gene, which is sensitive
to 5-fluorocytosine [75]. In animal experiments it has been
suggested that parasites carrying drug-sensitive cassettes
could provide suitable candidates for leishmanization as
an effective treatment of non-resolving lesions could be
guaranteed. But no such formulation has reached even in
pre-clinical stage as yet. In a clinical trial of live vaccine, in
Iran, several live Leishmania major stabilates were pro-
duced from the seed lots for challenge studies. The stabi-
lates were made from the late stationary phase of parasites
in culture and were kept frozen in liquid nitrogen, until
used. Two leishmanization trials were conducted in 42 in-
oculations in 28 male adult volunteers who were followed
until complete healing of their lesions [5]. However, intro-
duction of live attenuated Leishmania vaccine is not pos-
sible in an area with a risk of HIV infection.
Recently, live attenuated L. donovani centrin deleted
parasites have shown to elicit protective immunity against
leishmanial infection in mice and hamster models [76].
Some researchers also have used genetically engineered
ascorbic acid-deficient live mutants of L. donovani which
induced long-lasting protective immunity against visceral
Table 1 Vaccines used for leishmaniasis
Antigen Disease Vaccine type Animal model Result/Outcome Reference
No. (year)
Centrin deleted live parasite L. donovani VL Live (Genetically modified) Dogs Protection [76] (2015)
Ascorbic acid-deficient live mutants of L. donovani VL Live (Genetically modified) Mouse Protection [77] (2015)
Leishmania parasites lacking essential genes like
dyhydrofolate reductase, biopterin reductase and
cystein proteases
CL (L. max) Live (Genetically modified) Mouse Partial protection [79] (2015)
CL (L. m.)
p27 gene knockout L. donovani parasites VL (L. d.) Live attenuated Mouse Protection [82] (2013)
L. major (ALM) + BCG VL & PKDL Killed vaccine Mouse Partial protection [5] (2006)
KBMA L. infantum and L. chagasi VL Killed vaccine Mouse Partial protection [86] (2012)
Leishmune (FML) VL (L. d.) Fractioned vaccine Dogs Partial protection [88] (2006)
KMP 11 CL (L. m.) Recombinant vaccine Hamster Protection [94] (2005)
Leish F1 VL (L. d.) Recombinant protein Clinical trial Protection [92, 93] (2011)
Leish 111f VL (L. d.) Recombinant vaccine Mouse Protection [99] (2007)
HASPB1 VL (L. d.) Recombinant protein Mouse Partial protection [95] (2000)
Leish-f1+MPL-SE VL (L. I) Recombinant vaccine Clinical trial Protection [93] (2011)
rSMT VL (L. d.) Recombinant vaccine Mouse Protection [102] (2007)
A2 VL (L. i.) Recombinant vaccine Mouse Partial protection [101] (2009)
Leish-110f VL (L. i) Recombinant vaccine Mouse Protection [98] (2009)
LD91+LD72+ LD51+LD31 VL (L.d.) Antigen cocktail vaccine Mouse Partial protection [109] (2009)
(P-8 PGLC) L. pifanoi Antigen cocktail vaccine Dog Partial protection [110] (2007)
rCDV-LACK, rCDV-TSA, and rCDV-LmSTI1 CL (L. m.) Antigen cocktail vaccine Dog Protection [113] (2015)
Gp63 VL (L.d.) DNA vaccine Mouse Partial protection [119] (2011)
TRYP VL (L. i.) DNA vaccine Dog Protection [121] (2009)
NH36 VL (L. d.) DNA vaccine Mouse Partial protection [123] (2009)
Proteophosphoglycans (PPGs) VL (L. d.) DNA vaccine Hamster Partial protection [124] (2009)
ORFF VL (L. d.) DNA vaccine Mouse Partial protection [127] (2009)
LPG 3 VL (L. i.) DNA vaccine Mouse Partial protection [128] (2014)
LEISHDNAVAX VL (L. i.) DNA vaccine Mouse Protection [130] (2015)
Abbreviations: VL Visceral Leishmaniasis, CL Cutaneous Leishmaniasis, PKDL Post kala-azar dermal leishmaniasis, L.d. L. donovani, L.i., L. infantum, L.m. L.major,
L.max, L. maxicana
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leishmaniasis [77]. Genetically modified Leishmania para-
sites lacking essential genes like dyhydrofolate reductase,
biopterin reductase or cysteine proteases have been shown
to stimulate protection against challenge with virulent
parasite strains [78, 79]. However, for the live attenuated
parasite vaccines, the primary barrier against widespread
use remains the absence of clear biomarkers associated
with protection and safety. Growth arrested live attenu-
ated Leishmania parasite amastigotes have been used as a
tool to develop vaccine candidates against VL [80]. It has
also been reported that the combination of live attenuated
parasite along with the cysteine proteinases and sand fly
salivary antigen provide enhanced the protective efficacy
[81]. Long-term protective immunity in BALB/c mice was
also observed by using the live attenuated L. donovani p27
gene knockout parasites [82]. Attenuated vaccines offer a
novel approach to immunization against leishmaniasis.
However, there are fears that the parasite may revert back
to a virulent form, particularly in HIV-positive persons
who might get a fulminant form of vaccine induced leish-
maniasis. The asymptomatic infections of visceral leish-
maniasis is another challenge as standard diagnostics
methods involving parasite detection in tissue aspirates is
morally and technically inappropriate for them; serology-
based tests cannot distinguish between uninfected,
antibody-positive individuals and asymptomatic infected
individuals. DNA-based diagnostic assays appear to most
precise but the low predicted parasite burden in the
asymptomatic carriers is again an issue. Therefore, devel-
oping tools that can predict progression to VL disease is
an urgent need to established enrolment criteria for vac-
cine trials as well as outlining end-points to assess the vac-
cine efficacy. We and others have earlier shown that a
significant number of exposed individuals may remain
asymptomatic for several months and finally a good per-
centage of these asymptomatic persons may self-heal the
infection. If these persons are vaccinated and if they de-
velop the disease at a later date, it will be herculean task
for national governments and insurance agencies to settle
the issues of compensation and media cry. Also, targeted
deletion of essential virulence genes can result in complete
destruction of the parasite or mutants that may not elicit
protective immunity [83]. Moreover, the problems associ-
ated with live vaccines are standardization and quality
control. Such problems are of least concern with the use
of killed parasites for vaccine candidates.
Killed parasite vaccines
Since the late 1930s, pioneering work of Brazilian scien-
tists had demonstrated that killed parasites have efficacy
both as therapeutic and prophylactic vaccines against CL
and VL. The early trials with killed Leishmania as a vac-
cine were conducted in Brazil in the 1940s. Killed Leish-
mania is an appealing vaccine candidate in terms of its
stable biochemical composition and antigenicity, low
cost and safety, but the whole-parasite vaccine candi-
dates tested do not confer significant protection against
human leishmaniasis [84]. Over the ensuing decades,
numerous preparations of killed parasites were tested,
either alone or in combination with a variety of different
adjuvants. Although displaying well-tolerated safety pro-
files, to date, no first-generation vaccine using killed para-
sites has demonstrated sufficient efficacy as a prophylactic
vaccine to be used in widespread control programs [85].
Most vaccine studies focused on CL, and there have been
no clinical trials of first-generation vaccines produced
from and for visceralizing Leishmania spp. Killed parasite
vaccines using an alum-precipitated autoclaved L. major
(ALM) given with a BCG adjuvant had shown promise as
vaccines for VL and PKDL [5]. A whole-cell vaccine ap-
proach using L. infantum and L. chagasi promastigotes
has been used, after treating them with the psoralen com-
pound amotosalen and low doses of UV radiation. This
treatment generated permanent, covalent DNA cross-
links within parasites and resulted in Leishmania organ-
isms termed killed but metabolically active (KBMA). The
initial results were highly encouraging [86]. The killed
Leishmania vaccine has been applied for its immunogen-
icity in human and mouse models. The modern insights
into antileishmanial immunity offered possible explana-
tions for the failure of the first generation vaccines in the
field and have important implications for the vaccination
strategies against leishmaniasis. It has been demonstrated
that the inoculation of killed parasites into immune mice
leads to a loss of infection induced immunity. Recently,
Thakur et al. studied the protective efficacy of freeze-
thawed promastigote antigen of L. donovani along with
various adjuvants against visceral leishmaniasis infection
in mice [87]. As the killed parasite vaccine is conceptually
simple and easy to produce in leishmaniasis endemic
countries, at low cost. However, standardization of vaccine
derived from cultured parasites is difficult and it has hin-
dered commercial development efforts. In countries with
a rudimentary biotechnology industry and poor cold-
chain distribution system of vaccines, autoclaving of the
killed vaccine is the recommended method of sterilization
and preservation. However, autoclaving lowers the im-
munogenicity of the parasite by destroying most of the
proteins. Also, as the site of administration affects the effi-
cacy of a vaccine, it is important to investigate the most ef-
fective method and route of administration. Vaccination
with killed Leishmania parasite does not mimic natural in-
fection and is less immunogenic. No clinical trial of killed
vaccines has demonstrated a significant level of protection
for use of prophylactic vaccines. However, concerns re-
main regarding the feasibility of developing killed, whole-
parasite vaccines, including the variation in results ob-
tained from different fields and clinical trial sites in the
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past and potential difficulties in producing such a product
to good clinical manufacturing standards. Therefore, while
offering a safer and more stable alternative, killed parasite
vaccines warrant further investigation.
Leishmania fractionated vaccines
Leishmune, the first vaccine tried for canine visceral
leishmaniasis, consists of a purified L. donovani fraction,
named fructose mannose ligand (FML) and a saponin
adjuvant [88]. FML has been characterized as a major
antigenic complex of L. donovani and the main antigen
in this complex is NH36, an essential enzyme involved
in the construction of the parasite’s DNA [89]. Leish-
mune is considered a promising tool for the prevention
of canine visceral leishmaniasis and, furthermore, its po-
tential as a transmission-blocking vaccine is promising
for the control of zoonotic visceral leishmaniasis [90].
Partially or fully purified Leishmania fractions/subfrac-
tions have been widely used in experimental models
owing to their excellent immunoprotective properties.
Membrane antigens of L. donovani promastigotes (LAg)
entrapped in cationic liposomes (both positively and
negatively charged) could induce significant levels of
protection in mice [91]. However, difficulties in large-scale
production, standardization of in vitro culture conditions
and purification procedures are some of the issues raised
regarding these vaccines to be considered for clinical trials
against leishmaniasis. Therefore, focus has also been on
recombinant proteins, polyproteins, DNA vaccines and
dendritic cell vaccine delivery systems, as discussed in the
following sections.
Recombinant vaccines
Recombinant protein vaccines are produced by genetically
engineered cells to produce antigenic proteins [5]. Various
proteins have been tested as possible vaccine candidates.
The first candidate to reach phase I and II clinical trials
was LEISH-F1 from the Infectious Disease Research
Institute (IDRI, Seattle, WA) [92]. LEISH-F1 is comprised
of three proteins that are conserved across various Leish-
mania spp. including L. donovani and L infantum/L. cha-
gasi [93]. Other antigens included kinetoplastid
membrane protein-11 (KMP-11)-encoding construct, pro-
tected golden hamsters from both pentavalent antimony-
responsive (AG83) and antimony-resistant (GE1F8R) viru-
lent L. donovani challenges. Vaccinated hamsters showed
reversal of T cell anergy with functional IL-2 generation
along with vigorous specific anti-KMP-11 CTL-like re-
sponse. This was the first report of a vaccine conferring
protection to both antimony-responsive and resistant
Leishmania strains, reflecting several aspects of clinical
visceral leishmaniasis [94].
Recombinant hydrophilic acylated surface protein B1
(HASPB1), a member of a family of proteins expressed
only in metacyclic and amastigote stages, has shown effi-
cacy in an experimental mouse model of VL [95]. The
BALB/c mice were vaccinated with NH36 recombinant
protein and saponin followed by challenge with L. chagasi
amastigotes. The DTH response to leishmanial antigen
was significantly higher (70%) in vaccinees over the con-
trols [96]. The protective potential of cysteine proteinase
type III (CPC) has also been evaluated in BALB/c mice
by using a prime-boost strategy [97]. To date, only one
multicomponent vaccine, Leish-111F, has been assessed
in clinical trials. Leish-111F is a single polyprotein com-
posed of three molecules fused in tandem: the L. major
homologue of eukaryotic thiol-specific antioxidant (TSA),
the L. major stress-inducible protein-1 (LmSTI1), and the
L. braziliensis elongation and initiation factor (LeIF) [6].
An optimized version, known as Leish-111F, has recently
demonstrated strong immunogenicity and some protect-
ive efficacy against L. infantum in mice [98]. The Leish-
111F vaccine is moving forward into clinical trials as
LeishF1 and has been put on trial in combination with the
MPLSE adjuvant. This adjuvant consists of monopho-
sphoryl lipid A, a potent TLR4 agonist, formulated with
the antigen as a stable emulsion. A recent small-scale
clinical trial in a L. donovani endemic area showed
Leish-F1-MPL-SE was safe and well tolerated in people
with and without prior VL exposure and induced strong
antigen-specific T cell responses [92, 93]. Immune re-
sponse and protection induced by Leish-111F formulated
with monophosphoryl lipid A in a stable emulsion (Leish-
111F_MPL-SE) and demonstrated that mice developed
strong humoral and T-cell responses to the vaccine anti-
gen. Leish-111F/MPL-SE is the first defined vaccine candi-
date to progress to human phase-I and phase-II clinical
trials in healthy volunteers in South America, CL and ML
patients in Brazil and Peru and patients cured of VL in
India [93]. Analysis of the cellular immune responses of
immunized, uninfected mice demonstrated that the vac-
cine induced a significant increase in CD4 T cells produ-
cing gamma interferon, IL-2, and tumour necrosis factor
cytokines, indicating a Th1-type immune response [99].
Experimental infection of immunized mice and hamsters
demonstrated that Leish-111F_MPL-SE induced signifi-
cant protection against L. infantum infection, with reduc-
tions in parasite loads of 99.6%, a level of protection
greater than that reported for other vaccine candidates in
animal models of VL. Protective and immunostimulatory
effect of the prime-boost pORT-LACK/MVA-LACK
vaccination tested in a canine experimental model.
Vaccination induced a reduction in clinical signs and, in
parasite, burden in the liver, an induction of the Leish-
mania-specific T cell activation, as well as an increase of
the expression of Th1 type cytokines in PBMC and target
organs. The recombinant L. major H2B protein and its
amino-and carboxyl-terminal regions were evaluated for
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their ability to induce cellular responses in LCL-cured
subjects in order to assess their immunogenicity and
their potential use as vaccine candidates against cutaneous
and visceral leishmaniasis [100]. A recombinant L. taren-
tolae, expressing the L. donovani-specific A2 protein, was
used as a vaccine against L. infantum infection in BALB/c
mice and provided evidence that intravenous (i.v.) and,
to a larger extent, intraperitoneal (i.p.) immunization
with the recombinant L. tarentolae-A2 strain elicited
favourable immune responses and significant levels of pro-
tective immunity against L. infantum infectious challenge
[101]. The L. infantum sterol 24-c-methyltransferase
(rSMT) has been reported as a protective vaccine against
experimental VL [102]. Four new antigenic proteins S4,
S6, L3 and L5, located in Leishmania ribosomes have been
characterized as the prophylactic properties of these pro-
teins were first studied in the experimental model of cuta-
neous leishmaniasis caused by L. major inoculation into
BALB/c mice. The administration of two of them, LmL3
or LmL5 combined with CpG-oligo-deoxy-nucleotides
(CpG-ODN), was able to protect BALB/c mice against L.
major infection [103]. A cellular immune response to
PpSP15, a protein from the sand fly Phlebotomus papa-
tasi, was used as a vaccine for L. major infection in mice
in combination with CpG as a prime-boost. Modality con-
fers strong protection against L. major infection [104].
However, the experiments are currently in progress to
investigate if the changes in the immune response
after infection with the mutant parasite could provide any
protection against the challenge with the wild type para-
site. Saljoughian and colleagues used recombinant L. tar-
entolae expressing the L. donovani A2 antigen along with
cysteine proteinases [CPA and CPB without its unusual
C-terminal extension (CPB -CTE)] as a tri-fusion gene.
It showed that immunization with both prime-boost
A2-CPA-CPB(-CTE)-recombinant L. tarentolae pro-
tects BALB/c mice against L. infantum challenge [105].
Immunogenicity of Leish-Tec®, an A2-based vaccine for
visceral leishmaniasis, has been studied in a heteroge-
neous canine population by evaluating induced anti-
body responses [106]. The immunization with the L.
infantum recombinant cyclophilin protein-1 confers
partial protection to subsequent parasite infection and
generates specific memory T cells [107]. The role of
immuno-stimulatory proteins of Leishmania has been
used as a potent candidate for vaccine development
against leishmaniasis [108].
Antigen cocktail vaccines
Present progress to design vaccines agent against VL
is also based on molecularly defined antigens, the second-
generation vaccines. A large number of leishmanial
antigens against experimental leishmaniasis have been
attempted for vaccination; antigens LD91 (91-kDa), LD72
(72-kDa), LD51 (51-kDa) and LD31 (31-kDa) entrapped
in cationic liposomes as the adjuvant can be potential
components of future anti-leishmaniasis vaccines [109].
The P-8 proteoglycolipid complex (P-8 PGLC), an amasti-
gote antigen of L. pifanoi, has been demonstrated to in-
duce protection in the experimental model of canine
visceral leishmaniasis [110]. The ability of 6 pre-clinical
vaccine candidates have been evaluated to stimulate per-
ipheral blood T cells of cured VL patients by measuring,
the release of Th1 and Th2 cytokines. Such antigens in-
clude kinetoplastid membrane protein-11 (KMP11), sterol
24-c-methyltranferase (SMT), A2, cysteine proteinase B
(CPB), K26/HASPB and nucleoside hydrolase (NH). Fur-
thermore, these antigens produce a Th1- type immune re-
sponse, suggesting that they may elicit good protection
[111]. The identification as vaccine candidates of Leish-
mania antigens that elicit appropriate immune responses
in the canine model is a key step in the rational approach
to generate a vaccine for human visceral leishmaniasis
[112]. Recently, a cocktail of rCDV-LACK, rCDV-TSA,
and rCDV-LmSTI1, respectively, has been evaluated in
dogs and found markedly protective [113].
DNA vaccine
Most vaccine studies aim to limit parasite replication in
the vertebrate host and this approach has been appreci-
ated but also has some limitations. Over the past two
decades, several investigators have searched for genes
encoding leishmanial proteins that induce protection
against CL and VL in experimental mode. DNA vaccines
have leapfrogged from scientific curiosity to one of the
most dynamic fields of research and may offer new alter-
natives for the control of infectious diseases. DNA vac-
cines induce a complete immune response against the
encoded antigen [114]. DNA vaccines represent one of the
most recent innovations in the field of immunization.
DNA vaccines have been shown to induce a preferentially
Th1 immune response, which is necessary for the elimin-
ation of intracellular parasites and are thus a promising
strategy to control leishmaniasis [115]. Since the immune
defence against Leishmania infection and cure from dis-
ease involves adaptive and innate cellular immune re-
sponses, it is perceivable that immunity depends on
pathogen-specific CD4+ and CD8+ T cells with regulatory
as well as effector functions of phagocytic effector cells
[116, 117]. The Leishmania homologue for the receptors
of activated C kinase (LACK), is the most extensively
studied DNA vaccine against both cutaneous and visceral
leishmaniasis, but it has shown inconsistent results. Heter-
ologous prime-boost with gp63 antigen, with CpG-ODN
as adjuvant, provided durable protection against L. dono-
vani challenge in an experimental mouse model and was
associated with robust cellular immune responses [118].
As gp63 is a major surface protein present in both
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amastigote and promastigote forms and shows a high
homology between VL species [119], Intramuscular vac-
cination of foxhounds with a Leishmania multicomponent
(10 antigens) DNA vaccine resulted in antigen-induced
lymphoproliferative and IFN-γ (but not IL-4) responses in
primed dogs. The response was parasite-specific type 1
and it was able to restrict parasite growth [120]. A prime/
boost DNA/modified vaccinia virus Ankara vaccine ex-
pressing recombinant Leishmania DNA encoding TRYP is
safe and immunogenic in outbred dogs; it showed
antigen-specific type-1 responses and in vivo memory
phase cellular immune responses, consistent with superior
potential for protective vaccine [121]. Immunotherapy
against VL with the nucleoside hydrolase-DNA vaccine of
L. donovani was carried out and the vaccine was highly ef-
fective as a new tool for the therapy and control of VL
[122]. The NH36 gene of L. donovani, as a DNA vaccine,
followed by the FMLSAP vaccine, induce significant
cross-protective response against tegumentary leish-
maniasis induced by L. amazonensis, indicating its po-
tential use as a bivalent vaccine against visceral and
tegumentary leishmaniasis. The polytope approach of
genetic immunization is a promising strategy for the
prevention of infectious disease as it is capable of gen-
erating effective cell mediated immunity by delivering
the T cell epitopes assembled in the series [123]. Leish-
mania produces several types of mucin-like glycoproteins
called proteophosphoglycans (PPGs), the DNA-encoding
N-terminal domain of the ppg gene was evaluated as a vac-
cine in golden hamsters (Mesocricetus auratus) against
the L. donovani challenge. The prophylactic efficacy to the
tune of 80% was observed in vaccinated hamsters and all
of them could survive beyond 6 months, after challenge.
The efficacy was supported by a surge in inducible NO
synthase, IFN-γ gamma, TNF-α and IL-12 mRNA levels,
along with extreme down-regulation of TGF-β, IL-4, and
IL-10. A rise in the level of Leishmania-specific IgG2 was
also observed, which was indicative of enhanced cellular
immune response [124]. Non-coding pDNA bearing im-
mune stimulatory sequences co-entrapped with leishman-
ial antigens in cationic liposomes elicits almost complete
protection against experimental visceral leishmaniasis in
BALB/c mice [125]. An additional advantage of DNA vac-
cines is their potential as therapeutic vaccines, aimed at
reinforcing or redirecting the immune response of an in-
fected host to control disease progression [126]. The
ORFF protein is present in both promastigote and amasti-
gote forms of the parasite, but is preferentially expressed
in L. donovani amastigotes [127]. Ubiquitin conjugation
of ORFF DNA vaccine leads to improved cell-mediated
immune response and induces protection against both
antimony-sensitive and resistant strains of L. donovani
[127]. Lipophosphoglycan which is essential for the syn-
thesis of glycoconjugates as parasite virulence factors
have also been used for the evaluation of the immuno-
genicity of L. infantum LPG3 gene as a DNA vaccine
against murine visceral leishmaniasis [128]. The L.
amazonensis experimental infection has been analysed
by using DNA vaccine encoding iron superoxide dis-
mutase [129]. LEISHDNAVAX, a multi-antigen T-cell
epitope-enriched DNA vaccine, has been proved im-
munogenic and showed prophylactic efficacy in preclin-
ical studies. Riede et al. described the safety testing of
LEISHDNAVAX in naïve mice and rats, complemented
by the demonstration of tolerability in Leishmania-in-
fected mice [130]. The study indicated a favourable safety
profile of LEISHDNAVAX in both naïve and infected ani-
mals and thus, supports the initiation of clinical trials for
both preventive and therapeutic applications of the vac-
cine. Tabatabaie et al. investigated the protective efficacy
of TSA-based DNA vaccine against L. major infection and
it induced Th1 platform immune response and aluminium
phosphate could improve the efficacy with induction of
humoral and cellular immune responses against L. major
infection [131]. In susceptible BALB/c mice, DNA vaccin-
ation with the preparation, encoding Lipophosphoglycan 3
of L. infantum showed elicit robust parasite-specific pro-
tective Th1 responses [128].
DNA vaccines present a multitude of advantages over
other vaccine strategies and several features have made
them an appealing alternative [4]. DNA vaccines may
provide better protection against Leishmania than killed
or live-attenuated vaccines as they can induce the expres-
sion of Leishmania antigens, which are unaltered in their
protein structure and antigenicity [4]. However, delivery of
DNA vaccines is an important concern. Vaccination with
plasmid DNA encoding protective Leishmania antigens
gives a promising approach to vaccination against leish-
maniasis in that it has intrinsic adjuvant properties, in-
duces both humoral and cell-mediated immune responses
and results in long lasting immunity. However, the DNA
vaccines for human trial are still awaited eagerly as none
of those shown promising effects as per the clinical trial.
Chimeric DNA vaccines
In the aspect of developing an anti-leishmanial vaccine,
our laboratory has been working on immunological po-
tential of the kinesin motor domain region of the L.
donovani as a potential vaccine candidate against VL
[132]. The kinesin motor domain of L. donovani is also a
member of the kinesin protein superfamily. In L. dono-
vani, it has been found to play an important role in cell
division and intracellular transport of various cargoes in-
cluding vesicles, organelles, large protein complexes and
cytoskeletal filaments and is highly conserved in nature,
at the nucleotide sequence level. Our laboratory has
characterized the kinesin gene from two Indian isolates of
L. donovani (GenBank acc. no. AY615886 and AY615887).
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The sequencing results revealed that the kinesin gene
is ~ 3,000 bp long, comprising of one long open reading
frame (kinesin motor domain), followed by immune
dominant repeat region with 4–6 tandem repeats of
117 bp [133]. It has been reported that about 20% VL
patients will also have tuberculosis in TB high burden
countries like India. The esat-6 gene of M. tuberculosis
has earlier been shown to have diagnostic [Patent # WO
2010/010577 A] as well as immunogenic potential against
tuberculosis and likewise kinesin motor domain has
vaccine potential against visceral leishmaniasis. Both
organisms are intracellular pathogens leading to chronic
infection and have several similarities. Therefore, we
developed a novel chimeric DNA vaccine candidate com-
prising the esat-6 gene of M. tuberculosis and kinesin
motor domain gene of L. donovani [134]. Both genes were
cloned together on two sides of self-cleaving peptide
in a DNA vaccine vector pVAX-1 wherein the
chimeric construct is operatively linked to a transcriptional
promoter thus capable of self-replication and expression
within the mammalian cell. Further, immunogenicity of
chimera DNA vaccine was also studied and the immune
response compared to individual as well as chimeric clones
in a mice model. The chimeric DNA construct generated
cellular immune response with significant increase in
IFN-γ and IL-2 cytokine levels, which was an indication of
Th1 immune response (P < 0.05). Whereas the level of the
IL-4 and IL-6 markers of Th2 response, were found
comparatively lower. Our result of cellular immune re-
sponse suggested that, our novel chimeric DNA vaccine
could be as a potential immunoprotective candidate and
have important implications in future vaccine design.
This may offer an attractive alternative strategy against
leishmaniasis and tuberculosis co-infection [134].
Recent vaccine field trials
The transition from laboratory testing for evaluation in
the field condition is a significant phase in the develop-
ment of vaccine against any disease. There are a range
of issues coupled with this transition, including safety
and benefit to the patient or community. These limita-
tions raise complex human ethical issues in the quest for
successful vaccine development. Furthermore, a careful
understanding of defensive immune prophylaxis and im-
munological memory maintenance is equally significant
in vaccine trials.
Development of a successful vaccine to prevent kala-
azar has been an objective for nearly a century, but as of
now, no such vaccine has reached to the level of clinical
use. The only vaccine, which has reached to clinical tri-
als is Leish-111F [5, 92]. There is some evidence that the
Leish-111F vaccine can also induce partial protection
against visceral leishmaniasis in animal models. How-
ever, Leish-111F failed to protect dogs against infection
and did not prevent disease development in a recent
phase III trial in dogs. Human Phase I and II clinical
trials (safety and immunogenicity) of Leish-111F has
been completed over the past few years in Brazil,
Peru and Columbia, and Phase I trial has been conducted
in India [135].
Leishmania vaccine: a challenge may become a reality
For the controlling of any infectious disease, it is the
vaccination, which can be used as a cost-effective mean.
Various vaccines have successfully been used for control-
ling various infections, and even to complete eradication
of diseases like smallpox and polio. Like other infectious
diseases, leishmaniasis also ought to be controllable by
vaccination in view of the body of evidence from studies
in humans and animal models. Yet, no vaccine is cur-
rently in the market despite much effort. Therefore, the
question arises what are the reasons or limitations in de-
veloping a successful anti-leishmanial vaccine? In our
opinion, some of the key issues are:
1. Marginal or no profitable recovery from the market:
Vaccines against infections of the 3rd World such as
schistosomiasis, malaria, leishmaniasis and several
viral and bacterial diseases are unattractive to the
industry in view of financial profits, since the market
is not sufficiently lucrative to recover the cost of the
development (300 to 800 million US dollars per
vaccine development program) [136]. WHO and
several charitable foundations, such as the Bill and
Melinda Gates Foundation, contributing greatly to
the development of anti-parasitic vaccines and leish-
maniasis is on their list. Public-private partnerships
have also been suggested and the idea seems to have
been taken on board by Big Pharma companies.
2. Failure in conferring the immunity:
Soon after the Leishmania infection individuals are
considered to have acquired long-lasting immunity
to infection with the similar parasite, making vaccin-
ation a practical measure. However, despite of many
promising vaccine candidates, developing a vaccine
against human leishmaniasis is still difficult. The
killed vaccine candidates have concerns of lot viabil-
ity and good protective immunity, the live attenu-
ated vaccines have the danger of vaccine induced
leishmaniasis in immunosuppressed individuals like
AIDS patients. The recombinant and DNA vaccines
are in their initial phases and more data are yet to
come. Side effects are another issue with these gen-
etically modified vaccine candidates.
3. Suitability of adjuvant:
Development of an effective vaccine requires precise
information about the adjuvant to be used and the
specific formulation which makes it stable, safe and
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immunogenic. The suitability of the adjuvant
depends on factors such as the nature of antigen
(associated/co-administered), the route of
administration, the immunization schedule, and the
type of required immune response. However, these
parameters vary on a case to case basis in order to
develop an effective vaccine.
4. Differences in virulence dynamics of the Leishmania
species:
The clinical manifestation of Leishmania infection is
diverse, ranging from the cutaneous to visceral form.
Within these categories, Leishmania infection is able
to produce a large variety of atypical and rare
variants. The diversity is due to variation in the
causative species of Leishmania of New World and
Old World. For example, despite causing cutaneous
disease, the Old and New World parasites, L. major
and L. mexicana/L. amazonensis, respectively, are
markedly different. Phylogenetic analysis has
revealed that L. major is as distantly placed from L.
mexicana/L. amazonensis as it is from L. donovani,
which causes an entirely different disease. There are
differences in virulence factors among these species
as well as in the immune responses that they induce.
These major problems are currently hampering
the anti-leishmanial vaccine development and
implementation. The ethnicity of the host is
another important confounding factor.
Conclusion
Leishmaniasis is a group of different manifestations and
is the foremost cause of morbidity and mortality,
throughout the world. The preventive vaccines are rec-
ognized as the best and most cost-effective protection
measures against infectious pathogens, and theoretically
Leishmania should not be the exception. Effective vac-
cine will be crucial to meet the target to eliminate leish-
maniasis from the Indian subcontinent by 2020. In spite
of the availability of various therapeutic agents with
greater success and tremendous achievement in control-
ling the disease, there is no effective vaccine available for
visceral leishmaniasis, the most severe form of the infec-
tion. Leishmania vaccine development has proven to be
a difficult and challenging task, which is mostly ham-
pered by inadequate knowledge of parasite pathogenesis
and the complexity of immune responses needed for
protection. The parasites activate the innate and adap-
tive arms of the immune system, and it is clear that a co-
ordinated network of responses is required for effective
immune-mediated parasite clearance. Success of vaccine
development depends upon understanding the immuno-
biology of pathogen/host interactions, selection of ap-
propriate vaccine candidates and choosing the right
adjuvant or delivery vehicle. Currently, there seem to be
many problems, even though we are getting closer to de-
velop a safe and effective leishmaniasis vaccine(s). It is
becoming possible with the help of newer technological
advances and developments in the vaccinology field,
which have evolved from whole irradiated live parasites,
to the use of defined antigens such as LEISH-F, includ-
ing the DNA vaccines. Therefore, our efforts must con-
tinue in the quest of safe and practical vaccine to
eliminate this parasitic disease from the world.
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